EN DE
Watch CHA Biotech Co. Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CHA Biotech Co. Ltd (085660) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of CHA Biotech Co. Ltd stock KRW 7,611, price KRW 7,340, upside +3.7%, quality 17 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7085660009

CB CHA Biotech Co. Ltd logo Thin data Nov 10, 2026

CHA Biotech Co. Ltd

085660 · KQ
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Ranks above peers (7/11)
Fair value 7,611 KRW · Fairly valued
Expensive Growth (revenue 5y +13.8 %/yr in KRW)
Thin margins · 1.1% net margin (TTM)
Moderate debt
Quality 17/100
Negative free cash flow
Narrow moat 12/100 · thin data
Thin data
Estimate
Watch CHA Biotech Co. Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

27,279 KRW 6,720 KRW Fair Value 7,611 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 6,720 KRW – 27,279 KRW · fair‑value band 5,708 KRW – 9,514 KRW · the 7,340 KRW price screens below the 7,611 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow CHA Biotech Co. in your weekly email

Every Wednesday you see whether CHA Biotech Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally.

Show moreShow less

The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience.

It offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare.

In addition, the company develops immune cells, such as CBT101 for recurrent glioblastoma and solid cancer, and CBT111 and CAR-NK for solid cancer; and stem cells, including CordSTEM-DD for chronic back pain, CordSTEM-POI for premature ovarian failure, CordSTEM-ST for stroke, CBT-NPC for Parkinson's disease, and hESC-RPE for macular degeneration and Stargardt's disease.

Further, it offers IVF (fertility) services; cosmetics and cosmetic raw materials; medical devices and supplies; bioinsurance storage; research services; and other services. The company was founded in 2002 and is headquartered in Seoul, South Korea.

Stock analysis

CHA Biotech Co. Ltd (085660) currently trades at 7,340 KRW, while our estimate is 7,611 KRW, so the stock looks roughly fairly valued today (gap 3.6%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 5,708 KRW (bear) to 9,514 KRW (bull), the price of 7,340 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 17/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

CHA Biotech Co. Ltd reported revenue of 1.3T KRW in FY2025 versus 727B KRW in FY2021, a compound +14.9%/yr. Reported net income was −110B KRW in FY2025.

Key figures

Market cap 676B KRW (≈ $507M) Small · P/E ratio 48.3 · P/S ratio 0.52 · EPS (TTM) 153.51 KRW · Net margin 1.1% · Return on equity −1.8% · Return on assets (EBIT) −1.6% (5-year average) · Operating margin −8.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 69% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 4%, 085660 screens cheaper than that median.

Fair Value

Bear 5,708 KRW Fair Value 7,611 KRW Bull 9,514 KRW
Price 7,340 KRW · Upside +3.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 17/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 12
How much profit the company makes from its sales and capital
Quality Growth 47
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 9
Debt, balance sheet and risk of trouble
Investment 51
Does it invest with discipline instead of growing at any price?
Low Volatility 49
How calm the share price moves, does not count
Price momentum 8
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+21.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.8%
Start year 2020 (pandemic). Over 10 years: +12.4% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−0.9% (2020) → −3.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 085660, get fair value alerts →

Compare CHA Biotech Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 17 · Bottom 25%
Fair Value upside +3.7% · Top 25%
Profitability
Return on assets −4.3% · Above median
Net margin (12 months) 1.1% · Above median
Operating margin (12 months) −8.9% · Below median
Growth and dividend
Revenue growth (quarter YoY) 5.9% · Above median
Balance sheet
Debt / equity 0.53× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 48.3× · Pricier than median
P/B 2.22× · Cheaper than median
P/S (12 months) 0.52× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)38 · sector 0
FUTURE (revenue growth)30 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)74 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 085660
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 085660
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 085660
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 085660
argenx SE ARGX $971.55 $908.40 −7% vs 085660
CSL Limited CSL A$201.68 A$181.40 −10% vs 085660
Moderna, Inc MRNA $250.83 $158.70 −37% vs 085660
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 085660
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 085660
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 085660

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CHA Biotech Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CHA Biotech Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/085660

Frequently asked questions

Is CHA Biotech Co. Ltd (085660) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 7,611 KRW versus a price of 7,340 KRW, about +4% upside (fairly valued).
What is the fair value of 085660?
Our estimate for CHA Biotech Co. Ltd is 7,611 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 7,340 KRW.
What is the quality score of 085660?
CHA Biotech Co. Ltd has a Quality Score of 17/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CHA Biotech Co. Ltd (085660)?
Our calculated price target is the estimate of 7,611 KRW (as of Nov 10, 2026). Cautious scenario 5,708 KRW, optimistic scenario 9,514 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the CHA Biotech Co. Ltd stock forecast for 2026?
Our estimate puts fair value at 7,611 KRW, about +4% upside versus a price of 7,340 KRW (fairly valued). Cautious scenario 5,708 KRW, optimistic scenario 9,514 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of CHA Biotech Co. Ltd (085660)?
CHA Biotech Co. Ltd reported trailing-twelve-month revenue of about 1.3T KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of CHA Biotech Co. Ltd (085660)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CHA Biotech Co. Ltd it is 7,611 KRW per share (as of Nov 10, 2026), against a price of 7,340 KRW.
Is CHA Biotech Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 085660 trades below its calculated fair value: price 7,340 KRW, fair value 7,611 KRW, a gap of about +4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 085660?
No. The price is what the market pays today (7,340 KRW); the fair value is what the company's own numbers justify (7,611 KRW). For CHA Biotech Co. Ltd the two are 271.12 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is CHA Biotech Co. Ltd worth?
The market values CHA Biotech Co. Ltd at about 676B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 7,340 KRW; our models calculate a fair value of 7,611 KRW per share.
What do the bullish and bearish scenarios say about 085660?
Our models span a range for CHA Biotech Co. Ltd: cautious scenario 5,708 KRW, base 7,611 KRW, optimistic 9,514 KRW per share (as of Nov 10, 2026, price 7,340 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 085660?
CHA Biotech Co. Ltd trades at a price-to-earnings ratio of 48.3 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 7,611 KRW is built from several models across several years. Other multiples: P/B 2.2, P/S 0.5.
How solid is the balance sheet of CHA Biotech Co. Ltd (085660)?
Balance-sheet figures for CHA Biotech Co. Ltd (as of Nov 10, 2026): return on equity −1.8%, debt of 0.53 per unit of equity. They feed the Quality Score of 17/100, which measures business quality independently of the share price.
How far is 085660 from its 52-week high?
CHA Biotech Co. Ltd trades at 7,340 KRW, about 69% below its 52-week high of 23,850 KRW and 9% above the low of 6,720 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 7,611 KRW is for.
Which stocks are comparable to CHA Biotech Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CHA Biotech Co. Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price 7,340 KRW, calculated fair value 7,611 KRW (+4%), Quality Score 17/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. CHA Biotech Co. Ltd currently trades 4% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CHA Biotech Co. Ltd (085660)?
The closing price on Nov 10, 2026 was 7,340 KRW. Our estimate is 7,611 KRW, about +4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CHA Biotech Co. Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of CHA Biotech Co. Ltd

How large is the market capitalisation of CHA Biotech Co. Ltd (085660)?
The market capitalisation of CHA Biotech Co. Ltd is 676B KRW (≈ $507M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CHA Biotech Co. Ltd (085660)?
The price-to-sales ratio of CHA Biotech Co. Ltd is 0.52 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CHA Biotech Co. Ltd (085660)?
Earnings per share at CHA Biotech Co. Ltd are 153.51 KRW (price ÷ EPS = P/E 48.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of CHA Biotech Co. Ltd (085660)?
The net margin of CHA Biotech Co. Ltd is 1.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CHA Biotech Co. Ltd (085660)?
The return on equity (ROE) of CHA Biotech Co. Ltd is −1.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CHA Biotech Co. Ltd (085660)?
On an EBIT basis the return on assets of CHA Biotech Co. Ltd is −1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CHA Biotech Co. Ltd (085660)?
The operating margin of CHA Biotech Co. Ltd is −8.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CHA Biotech Co. Ltd (085660)?
Revenue at CHA Biotech Co. Ltd is growing +5.9% versus a year earlier (3y avg +14.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CHA Biotech Co. Ltd (085660)?
Earnings per share at CHA Biotech Co. Ltd are growing −25.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does CHA Biotech Co. Ltd (085660) generate?
The free cash flow of CHA Biotech Co. Ltd is −225B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does CHA Biotech Co. Ltd (085660) carry?
The net debt of CHA Biotech Co. Ltd is 580B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch CHA Biotech Co. Ltd in the live analysis

One click puts CHA Biotech Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.